Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

By M. Kim, H. Kwon, Y. M. Lee, J. Baek, Jae-Eun Jang, Sae-Won Lee, E. Moon, Hae-Sun Kim, Seok-Ki Lee, H. Chung and 2 more. Nature Medicine, 2001

765 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/1ac5e824b0427589b32744b566956934ebeeed52

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

Hypoxia — a key regulatory factor in tumour growth (2002, background): “A specific HDAC inhibitor, trichostatin A (TSA), reduces hypoxia-induced angiogenesis in the Lewis lung carcinoma mode”
Histone deacetylases and cancer: causes and therapies (2001, background): “Both TSA and depsipeptide are reported to block angiogenesis in vivo”
FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. (2001, background): “Interestingly, HDAC1 mRNA and protein expression are induced by hypoxia (Kim et al. 2001), suggesting that HDAC1 may represent a HIF-1 target gene and that increased HDAC activity may contribute to the overall decreased rate of transcription in hypoxic cells.”
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, background): “Under hypoxic conditions trichostatin A (TSA) has been shown to upregulate VHL and p53 while downregulating VEGF and HIF 1α to block angiogenesis [171].”
Hypoxia-Inducible Factor-1 (HIF-1) (2006, neutral): “In addition, artificial maintenance or increase of the acetylated state of HIF-1α by butyric acid, a global inhibitor of deacetylases, caused decreased HIF-1α protein levels (Kim et al., 2001).”
SIRT1 controls endothelial angiogenic functions during vascular growth. (2007, background): “Class I and II HDACs play important roles in the transcriptional control of endothelial gene expression and vascular development (Kim et al. 2001; Deroanne et al. 2002; Rossig et al. 2002, 2005; Illi et al. 2003, 2005; Chang et al. 2006).”
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer (2002, background): “cgi?l=7422"> VEGF ) and suppress angiogenesis, both in vitro and in vivo”
Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. (2004, methodology): “Moreover, expression of VEGF and HIF-1 (hypoxia inducible factor-1, the main transcription factor activated by hypoxia) colocalize with hypoxic regions (as detected using the hypoxic cell marker, pimonidazole) in a murine model of Lewis lung carcinoma.(86) As mentioned previously, more TAMs are pres”